Abstract 2989
Background
Past and recent findings indicate that adverse effects of chemotherapy influence the patients’ quality of life. The aim of this study was to investigate the implicated factors that influenced the perceived symptoms and quality of life in cancer patients during chemotherapy.
Methods
A longitudinal study was conducted in a large hospital in a major city of Northern Greece. A total of 200 cancer patients undergoing chemotherapy in cycle 2 and cycle 3 were participated in the research. Data was collected using Memorial Symptom Assessment Scale (MSAS), Functional Assessment Cancer Therapy (FACT-G) additionally with a questionnaire for the demographic and clinical characteristics. Descriptive and conductive statistical methods were applied.
Results
The vast majority of the participants were middle aged (58.94±9.94 years) men (n = 122, 61%) suffering from lung cancer (n = 98, 48%). Analysis based on the chemotherapy cycle status revealed a significant differences in several factors grouping the patients regarding their chemotherapy cycle status (cycle 2 vs cycle 3). Particularly, feeling nervous level, severity and distress of dizziness and the severity in the way of food tastes [p = 0.014, p = 0.001, p < 0.001, p < 0.001 and p = 0.030, respectively] differed statistically significantly. Moreover, multiple logistic regression analysis revealed that gender (p < 0.001) and physical well-being score (p = 0.005) affected perceived symptoms in MSAS. Furthermore, gender, occupational status, diet, type of cancer and family status influenced the overall quality of life in cycle 2 patients (p = 0.002, p < 0.001, p = 0.002, p < 0.001 and p < 0.001 respectively); however, in cycle 3 patients : gender (p = 0.003), occupational status (p < 0.001), educational status (p < 0.001) and diet (p < 0.001) were referred as the most statistically significant variables that influence the overall quality of life.
Conclusions
In conclusion, we demonstrate that adverse effects of chemotherapy in cancer patients play a critical role for the overall quality of patients’ life. Patients demographic or/ and clinicobiological characteristics seem to influence the appearance of the adverse effects.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2888 - Development and validation a nomogram based on pathological microscopic features to predict survival in nasopharyngeal carcinoma and guide treatment decision
Presenter: Kuiyuan Liu
Session: Poster Display session 3
Resources:
Abstract
3607 - Deep learning in nasopharyngeal carcinoma: a retrospective cohort study of 3D convolutional neural networks on magnetic resonance imaging
Presenter: Meng Yun Qiang
Session: Poster Display session 3
Resources:
Abstract
5848 - Combined androgen blockade in patients with advanced androgen receptor–positive salivary gland carcinoma: Exploratory biomarker analyses
Presenter: Chihiro Fushimi
Session: Poster Display session 3
Resources:
Abstract
4484 - Classification of esthesioneuroblastoma (ENB) based on chromosome (chr) arm gain and loss (CNA) in the setting of a hypomutated genomic landscape
Presenter: Russell Madison
Session: Poster Display session 3
Resources:
Abstract
5753 - Trastuzumab plus docetaxel in patients with advanced HER2–positive salivary duct carcinoma: Exploratory biomarker analyses
Presenter: Hideaki Takahashi
Session: Poster Display session 3
Resources:
Abstract
3373 - Development and characterization of salivary gland cancer organoid cultures
Presenter: Wim Boxtel
Session: Poster Display session 3
Resources:
Abstract
3118 - A parent-of-origin effect of the RB1 mutations in retinoblastoma with low penetrance and variable expressivity
Presenter: Ekaterina Alekseeva
Session: Poster Display session 3
Resources:
Abstract
4512 - The humanistic burden reported by patients diagnosed with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) in Europe
Presenter: Prianka Singh
Session: Poster Display session 3
Resources:
Abstract
3961 - Concurrent Chemotherapy and External Radiation Therapy: An Open Label Non-Inferiority Phase III Randomized Controlled Trial of Weekly versus Three Weekly Cisplatin and Radical Radiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: CONCERT trial
Presenter: ATUL SHARMA
Session: Poster Display session 3
Resources:
Abstract
3973 - A randomized phase II study on the OPTimization of IMmunotherapy in squamous carcinoma of the head and neck (SCCHN) – OPTIM (AIO-KHT-0117)
Presenter: Viktor Grünwald
Session: Poster Display session 3
Resources:
Abstract